As a Condition of the Marketing Authorisation, the CHMP requested the MAH to commit to generate a collection of long-term data for the evaluation of long-term safety of risperidone in children and adolescents with conduct disorder in terms of potential effects on growth (height and weight), mental development, and sexual maturation (by Tanner stage).